Drug intelligence / Profile preview

RJV-200

Development stage: Preclinical
Lead developer: Rejenevie Therapeutics
Modality: Cell Therapies

Overview

RJV-200 is a **preclinical cell therapy** from **Rejenevie Therapeutics** designed for **aged stromal vascular fraction restoration using young mobilized blood**. The program is listed in the company's pipeline for **all Okyanos treating indications** and appears to be part of Rejenevie's regenerative medicine and immune-restoration platform being advanced in connection with the Okyanos clinical setting. No discrete molecular target has been publicly specified; instead, the therapeutic concept is restoration of aged stromal vascular fraction biology through administration of restorative components derived from young mobilized blood.

Other names: aged SVF restoration using young mobilized blood

Beyond the preview

Go deeper on RJV-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJV-200.

Explore the full profile